Journal article
Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies
MT Fodero-Tavoletti, S Furumoto, L Taylor, CA McLean, RS Mulligan, I Birchall, R Harada, CL Masters, K Yanai, Y Kudo, CC Rowe, N Okamura, VL Villemagne
Acta Veterinaria Scandinavica | BMC | Published : 2014
DOI: 10.1186/alzrt240
Abstract
Introduction: The introduction of tau imaging agents such as 18F-THK523, offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer's disease (AD), where preliminary 18F-THK523-PET studies demonstrated significantly higher cortical retention of 18F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value to assess non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick's disease (PiD). Methods: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescent studies in serial brain sections f..
View full abstractGrants
Awarded by Alzheimer's Drug Discovery Foundation
Funding Acknowledgements
We thank Fairlie Hinton and Geoff Pavey from the Victorian Brain Bank Network (VBBN) for sourcing and preparing the human brain tissue (HREC University of Melbourne 9414748). The VBBN is supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian Forensic Institute of Medicine, and it is funded by Australia's National Health & Medical Research Council (NHMRC) and Parkinson's Victoria. The research was supported in part by Alzheimer's Drug Discovery Foundation Research Grant 20101208 AFTD and NHMRC project grant 1044361.